🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06713876
Active, not recruiting Observational

Long-term Outcomes of Patients Undergoing ECMO-assisted PCI

NCT06713876 · tracked via the Priya Life Science China tracker
Sponsor
Ling Tao, MD, PhD
Phase
Observational
Started
2016-08-01
Last updated
2024-12-03

Condition(s) studied

Complex High-risk and Indicated Patients

Investigational drug(s) / intervention(s)

VA-ECMO-assisted PCI

VA-ECMO-assisted PCI: A total of 220 consecutive patients with VA-ECMO-assisted PCI will be enrolled. Data related to medical history, procedural characteristics, and outcomes were collected. Clinical follow-up will be conducted in the periprocedural and postoperative at 1 month, 1 year, 2 years, 3 years, 4 years, and 5 years.

Study summary

Evidence regarding the long-term outcomes of patients undergoing Veno-arterial extracorporeal membrane oxygenator (VA-ECMO) assisted percutaneous coronary intervention (PCI) and the impact of the operator experience is limited.

The purpose of this retrospective single-center, observational registry in China is to investigate the long-term outcomes of patients undergoing VA-ECMO-assisted PCI and the impact of the operator experience.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Aged 18 years or older 2. Coronary artery disease of the left main and/or multivessel disease 3. Combined with severely impaired left ventricular ejection fraction (LVEF), defined as LVEF ≤ 35% or decompensated heart failure 4. The heart team and the patient rejected CABG or OMT Exclusion criteria were VA-ECMO support applied for cardiogenic shock or extracorporeal cardiopulmonary resuscitation (ECPR)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xijing Hospital Xi'an Shaanxi
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06713876 on ClinicalTrials.gov ↗ ← All trials in China